Zinc supplementation suppresses 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis

Carcinogenesis

Volumn 32, Issue 4, 2011, Pages 554-560

  Fong, Louise Y Y ^a   Jiang, Yubao ^a   Rawahneh, Maysoon L ^b   Smalley, Karl J ^c   Croce, Carlo M ^b   Farber, John L ^a   Huebner, Kay ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; BIOLOGICAL MARKER; CYCLIN D1; CYCLOOXYGENASE 2; DRINKING WATER; PROTEIN P53; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DYSPLASIA; HISTOPATHOLOGY; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MALE; MOUTH CARCINOGENESIS; MOUTH CARCINOMA; NONHUMAN; PAPILLOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; ZINC DEFICIENCY;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DIETARY SUPPLEMENTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; TONGUE NEOPLASMS; ZINC;

EID: 79953710016     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr004     Document Type: Article

References (49)

1. Parkin,D.M. et al. (2001) Estimating the world cancer burden: Globocan 2000. Int. J. Cancer., 94, 153-156.
2. Makuuchi,H. et al. (1996) Endoscopic screening for esophageal cancer in 788 patients with head and neck cancers. Tokai J. Exp. Clin. Med., 21, 139-145.
3. Slaughter,D.P. et al. (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer, 6, 963-968.
4. Moore,S.R. et al. (2000) The epidemiology of tongue cancer: a review of global incidence. Oral Dis., 6, 75-84.
5. Doerr,T.D. et al. (1997) Zinc deficiency in head and neck cancer patients. J. Am. Coll. Nutr., 16, 418-422.
6. Kleier,C. et al. (1998) [Zinc and vitamin A deficiency in diseases of the mouth mucosa]. Mund Kiefer Gesichtschir., 2, 320-325.
7. Yang,C.S. (1980) Research on esophageal cancer in China: a review. Cancer Res., 40, 2633-2644.
8. van Rensburg,S.J. (1981) Epidemiologic and dietary evidence for a specific nutritional predisposition to esophageal cancer. J. Natl Cancer Inst., 67, 243-251.
9. Abnet,C.C. et al. (2005) Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk. J. Natl Cancer Inst., 97, 301-306.
10. Vallee,B.L. et al. (1993) The biochemical basis of zinc physiology. Physiol. Rev., 73, 79-118.
11. Rink,L. et al. (2007) Zinc homeostasis and immunity. Trends Immunol., 28, 1-4.
12. O'Halloran,T.V. (1993) Transition metals in control of gene expression. Science, 261, 715-725.
13. Prasad,A.S. et al. (2009) Zinc in cancer prevention. Nutr. Cancer., 61, 879-887.
14. Fong,L.Y. et al. (2005) Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats. J. Natl Cancer Inst., 97, 40-50.
15. Taccioli,C. et al. (2009) Zinc replenishment reverses overexpression of the proinflammatory mediator S100A8 and esophageal preneoplasia in the rat. Gastroenterology, 136, 953-966.
16. Fong,L.Y. et al. (2001) Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc. J. Natl Cancer Inst., 93, 1525-1533.
17. Fong,L.Y. et al. (2008) Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2. Int. J. Cancer., 122, 978-989.
18. Colotta,F. et al. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30, 1073-1081.
19. Hanahan,D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
20. Yoshida,K. et al. (2003) A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression. Histol. Histopathol., 18, 39-48.
21. McCormick,D.L. et al. (2010) Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. Cancer Prev. Res. (Phila.), 3, 73-81.
22. Wallenius,K. et al. (1973) Oral cancer in rats induced by the water-soluble carcinogen 4-nitrochinoline N-oxide. Odontol. Revy., 24, 39-48.
23. Tanaka,T. (1995) Chemoprevention of oral carcinogenesis. Eur. J. Cancer B. Oral Oncol., 31B, 3-15.
24. Tanaka,T. et al. (1989) Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Lett., 48, 177-182.
25. Shiotani,H. et al. (2001) Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res., 61, 1451-1456.
26. Tanaka,T. et al. (1993) Chemoprevention of oral carcinogenesis by DLalpha-difluoromethylornithine, an ornithine decarboxylase inhibitor: dosedependent reduction in 4-nitroquinoline 1-oxide-induced tongue neoplasms in rats. Cancer Res., 53, 772-776.
27. Sherr,C.J. (1995) D-type cyclins. Trends Biochem. Sci., 20, 187-190.
28. Dietrich,D.R. (1993) Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation. Crit. Rev. Toxicol., 23, 77-109.
29. Bartkova,J. et al. (1995) Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res., 55, 949-956.
30. Nakagawa,H. et al. (1995) Human cyclin D1 oncogene and esophageal squamous cell carcinoma. Cancer, 76, 541-549.
31. Greenblatt,M.S. et al. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
32. Zimmermann,K.C. et al. (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res., 59, 198-204.
33. Renkonen,J. et al. (2002) Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch., 440, 594-597.
34. Wan,S.G. et al. (2010) Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression. Int. J. Cancer.
35. Sun,J. et al. (2010) Effect of zinc supplementation on N-nitrosomethylbenzylamine-induced forestomach tumor development and progression in tumor suppressor-deficient mouse strains. Carcinogenesis, 32, 351-358.
36. Osugi,Y. (1996) p53 expression in various stages of 4-nitroquinoline1-oxide induced carcinoma in the rat tongue. J. Osaka Dent. Univ., 30, 29-35.
37. Yoshida,K. et al. (2003) Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci., 94, 365-371.
38. Pich,A. et al. (2004) Prognostic relevance of cell proliferation in head and neck tumors. Ann. Oncol., 15, 1319-1329.
39. Shin,D.M. et al. (1996) p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J. Natl Cancer Inst., 88, 519-529.
40. Fong,L.Y. et al. (2001) Alpha-difluoromethylornithine induction of apoptosis: a mechanism which reverses pre-established cell proliferation and cancer initiation in esophageal carcinogenesis in zinc-deficient rats. Cancer Epidemiol. Biomarkers Prev., 10, 191-199.
41. Fong,L.Y. et al. (1998) Zinc replenishment reduces esophageal cell proliferation and N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumor incidence in zinc-deficient rats. Carcinogenesis, 19, 1591-1596.
42. Azmi,A.S. et al. (2011) MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene, 30, 117-126.
43. Prasad,A.S. et al. (1978) Hypocupremia induced by zinc therapy in adults. JAMA, 240, 2166-2168.
44. Bao,B. et al. (2010) Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. Am. J. Clin. Nutr., 91, 1634-1641.
45. Clemons,T.E. et al. (2004) Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch. Ophthalmol., 122, 716-726.
46. Dani,V. et al. (2007) Chemopreventive potential of zinc in experimentally induced colon carcinogenesis. Toxicol. Lett., 171, 10-18.
47. Shah,M.R. et al. (2009) Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. J. Exp. Clin. Cancer Res., 28, 84.
48. Lin,L.C. et al. (2008) Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a doubleblinded randomized study. Int. J. Radiat. Oncol. Biol. Phys., 70, 368-373.
49. Lin,Y.S. et al. (2009) Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis. Laryngoscope, 119, 1348-1352.